Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat.
Pang. Jinjiang J; Xu. Qihua Q; Xu. Xiangbin X; Yin. Hongchao H; Xu. Rongkun R; Guo. Shu S; Hao. Wei W; Wang. Luya L; Chen. Chen C; Cao. Ji-Min JM
Key Findings
- Hexarelin lowered plaque formation and neointima thickness in a rat model of diet‑induced atherosclerosis.
- It partially restored the HDL‑c/LDL‑c ratio and increased serum nitric oxide and aortic eNOS, GHSR, and CD36 mRNA levels.
- Hexarelin inhibited vascular smooth‑muscle cell proliferation, calcium deposition in the aorta, and foam‑cell formation from oxidized LDL.
Practical Outcomes
- For biohackers, the study suggests that GHRP‑type peptides like hexarelin might offer cardiovascular protection beyond their GH‑releasing effects, but the evidence is limited to rodents. Until human trials confirm safety and effective dosing, any use for atherosclerosis prevention remains speculative and should be approached with caution.
Summary
In rats fed a high‑fat diet and vitamin D3, the peptide hexarelin (a growth‑hormone‑releasing peptide) reduced the buildup of atherosclerotic plaques, improved the good‑to‑bad cholesterol ratio, boosted nitric‑oxide production in blood vessels, and slowed the growth of vascular smooth‑muscle cells and foam‑cell formation.
Abstract
Growth hormone-releasing peptides (GHRP) and ghrelin are synthetic and natural ligands of growth hormone secretagogue receptor (GHSR) respectively and are shown to exert protective actions on cardiac dysfunction. Because ghrelin has been reported to inhibit proinflammatory responses in human endothelium and GHSR has been identified in blood vessels, we hypothesized that GHRP could alleviate the development of atherosclerosis (As). Atherosclearosis was induced by a short period (4 days) of vitamin D(3) and chronic (three months) intragastric feeding of high fat emulsion (containing 0.5% propylthiouracil) in adult SD rats. Some As rats received chronic hexarelin (a variant of GHRP) injection (SC BID, 30 days) and normal rats received placebo as control. Significant atherosclerosis developed in animals fed with the emulsion. Serum total cholesterol and LDL-c increased, and HDL-c and aortic nitric oxide (NO) decreased significantly in As group. Hexarelin suppressed the formation of atherosclerotic plaques and neointima, partially reversed serum HDL-c/LDL-c ratio and increased the levels of serum NO and aortic mRNAs of eNOS, GHSR and CD36 in As rats. Hexarelin also decreased [(3)H]-TdR incorporation in cultured vascular smooth muscle cell (VSMC) and calcium sedimentation in aortic wall. Furthermore, foam cell formation induced by ox-LDL was decreased by hexarelin. In conclusion, hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in rats, possibly through upregulating HDL-c/LDL-c ratio, vascular NO production and downregulating the VSMC proliferation, aortic calcium sedimentation and foam cell formation. These novel anti-atherosclerotic actions of hexarelin suggest that the peptide might have a clinical potential in treating atherosclerosis.
Study Information
pubmed
2009
2009-11-30T00:00:00.000Z
10.1016/j.peptides.2009.11.007
56
58